An update from Scholar Rock Holding (SRRK) is now available.
Scholar Rock Holding Corporation revealed promising results from a preclinical study at the American Diabetes Association’s 84th Scientific Sessions, which demonstrated potential benefits of their drug SRK-439 in combination with GLP-1 receptor agonists for weight management. In a mouse model, SRK-439 not only mitigated lean mass loss during treatment but also reduced fat mass rebound after the cessation of the drug. These findings suggest SRK-439 could offer a healthier body composition for those struggling with obesity. Additionally, the company has started a Phase 2 trial to evaluate the effectiveness of another drug, apitegromab, in preserving lean muscle mass in obese individuals.
For a thorough assessment of SRRK stock, go to TipRanks’ Stock Analysis page.
